Investors
Sustaining long-term profitable growth
Our goal is to create sustainable social and financial value, by helping accelerate the pace of discovery, and the translation of those discoveries into social impact. We are uniformly committed to responsibly pursuing that goal through our purpose and have a clear strategy to achieve this.
In September 2019, we set out the following strategic goals to guide our activities:
1. Sustain and extend our antibody and digital leadership (“Lead“)
2. Drive continued expansion into complementary market adjacencies (“Expand“)
3. Build organisational scalability and sustain value creation (“Scale“)
Underlying these goals are six growth strategies which form the foundation of our growth strategy and value creation plan for the medium-term. They are designed to help us grow together; not just as a Company, but as a global team, and to do so in an efficient and effective way.
Use the tabs below to explore our growth pillars and strategies:
1. Extend leadership in RUO antibodies
PILLARS: LEAD
Our growth strategy starts with a commitment to extending our antibody leadership. Fundamental to our purpose, we are committed to help advance and accelerate our customers’ research and, in turn, support our market share gains. We seek to do this through the ongoing curation and expansion of our product portfolio, combined with the addition of data, knowledge and information that demonstrates the performance and increased utility of those products in a broader range of experiments and applications.
Our strategy is enhanced through our focus on in-house proprietary products, including one of the world’s largest portfolios of recombinant rabbit monoclonal antibodies. Through continuous innovation we are focused on ensuring that our portfolio is aligned with the targets, research areas and biological pathways in highest demand from our customers.
2. Remove innovation constraints and launch new lines
PILLARS: EXPAND
We are developing our innovation capabilities to meet a broader range of our customers’ needs and grow within our addressable markets, including:
Antibody-based products for high-value markets
We are extending the range of products derived from our catalogue of in-house primary antibodies, including conjugated antibodies, antibody pairs, SimpleStep singleplex assays and Fireplex multiplex products;
Complementary product areas that increase antibody innovation capacity
Areas include bioactive proteins, as well as disease relevant engineered cell lines and associated cell lysates.
3. Be a leading discovery partner for biopharma organisations
PILLARS: EXPAND
Diagnostic and biopharmaceutical companies are increasingly seeking product development partners with unique antibody and assay development capabilities, such as ours, to complement their in-house programmes. Through our portfolio of high-performance in-house products, combined with a growing innovation, commercial and manufacturing capability, our goal is to be a leading discovery partner for these strategic customers. We believe this will lead to increased opportunities for the development of custom solutions, partnerships, and collaborations.
4. Be a leading digital company
PILLARS: LEAD
Our objective is to be a leading discovery partner to organisations looking to access high-quality antibodies and antibody expertise for commercial use by providing access to our portfolio of high-performance in-house products, our antibody and assay development expertise and commercial and manufacturing capabilities. This includes third party instrumentation platforms and multiplex partners developing novel platforms or upgrading their existing platforms. We believe this will lead to increased opportunities for the development of custom solutions, partnerships, and collaborations.
5. Remove scalability constraints and sustain value
PILLARS: SCALE
Our objective is to strengthen our teams, systems and infrastructure while driving operational efficiency. We are focused on increasing our manufacturing capacity, increasing automation at process bottlenecks and optimising our global network and procurement functions. We are also transforming our systems and processes by implementing Oracle Cloud enterprise resource planning (“ERP”) and other software solutions to replace legacy information technology systems.
6. Selectively pursue acquisitions
PILLARS: LEAD, SCALE, EXPAND
We have a strong track record of successfully identifying, completing and integrating strategic acquisitions and investments. Our strong brand, broad platform, global infrastructure and diversified customer base has allowed us to generate growth and operating leverage through acquisitions. We intend to continue to pursue opportunistic acquisitions in our existing and adjacent customer segments to accelerate our growth, expand geographic coverage and augment our capabilities and workflow solutions.
Sustain and expand antibody and digital leadership.
1. Extend leadership in RUO antibodies
Our growth strategy starts with a commitment to extending our antibody leadership. Fundamental to our purpose, we are committed to help advance and accelerate our customers’ research and, in turn, support our market share gains. We seek to do this through the ongoing curation and expansion of our product portfolio, combined with the addition of data, knowledge and information that demonstrates the performance and increased utility of those products in a broader range of experiments and applications.
Our strategy is enhanced through our focus on in-house proprietary products, including one of the world’s largest portfolios of recombinant rabbit monoclonal antibodies. Through continuous innovation we are focused on ensuring that our portfolio is aligned with the targets, research areas and biological pathways in highest demand from our customers.
4. Be a leading digital company
Our objective is to be a leading discovery partner to organisations looking to access high-quality antibodies and antibody expertise for commercial use by providing access to our portfolio of high-performance in-house products, our antibody and assay development expertise and commercial and manufacturing capabilities. This includes third party instrumentation platforms and multiplex partners developing novel platforms or upgrading their existing platforms. We believe this will lead to increased opportunities for the development of custom solutions, partnerships, and collaborations.
6. Selectively pursue acquisitions
We have a strong track record of successfully identifying, completing and integrating strategic acquisitions and investments. Our strong brand, broad platform, global infrastructure and diversified customer base has allowed us to generate growth and operating leverage through acquisitions. We intend to continue to pursue opportunistic acquisitions in our existing and adjacent customer segments to accelerate our growth, expand geographic coverage and augment our capabilities and workflow solutions.
Drive continued expansion into complementary market adjacencies.
2. Remove innovation constraints and launch new lines
We are developing our innovation capabilities to meet a broader range of our customers’ needs and grow within our addressable markets, including:
Antibody-based products for high-value markets
We are extending the range of products derived from our catalogue of in-house primary antibodies, including conjugated antibodies, antibody pairs, SimpleStep singleplex assays and Fireplex multiplex products;
Complementary product areas that increase antibody innovation capacity
Areas include bioactive proteins, as well as disease relevant engineered cell lines and associated cell lysates.
3. Be a leading discovery partner for biopharma organisations
Diagnostic and biopharmaceutical companies are increasingly seeking product development partners with unique antibody and assay development capabilities, such as ours, to complement their in-house programmes (see Our Markets). Through our portfolio of high-performance in-house products, combined with a growing innovation, commercial and manufacturing capability, our goal is to be a leading discovery partner for these strategic customers. We believe this will lead to increased opportunities for the development of custom solutions, partnerships, and collaborations.
6. Selectively pursue acquisitions
We have a strong track record of successfully identifying, completing and integrating strategic acquisitions and investments. Our strong brand, broad platform, global infrastructure and diversified customer base has allowed us to generate growth and operating leverage through acquisitions. We intend to continue to pursue opportunistic acquisitions in our existing and adjacent customer segments to accelerate our growth, expand geographic coverage and augment our capabilities and workflow solutions.
Build organisational scalability and sustain value creation.
5. Remove scalability constraints and sustain value
Our objective is to strengthen our teams, systems and infrastructure while driving operational efficiency. We are focused on increasing our manufacturing capacity, increasing automation at process bottlenecks and optimising our global network and procurement functions. We are also transforming our systems and processes by implementing Oracle Cloud enterprise resource planning (“ERP”) and other software solutions to replace legacy information technology systems.
6. Selectively pursue acquisitions
We have a strong track record of successfully identifying, completing and integrating strategic acquisitions and investments. Our strong brand, broad platform, global infrastructure and diversified customer base has allowed us to generate growth and operating leverage through acquisitions. We intend to continue to pursue opportunistic acquisitions in our existing and adjacent customer segments to accelerate our growth, expand geographic coverage and augment our capabilities and workflow solutions.
The more successful we can be as a business, the greater the difference we can make in the world. That extends to doing business the right way.
2021 Year in Review
Read about the financial and strategic progress made in 2021.
2021 Year in Review
Read about the financial and strategic progress made in 2021.
Our business model
Explore our business model and how we sustain value creation for our stakeholders
Our markets
Read about our markets and their long-term growth drivers
Our reports & presentations
View our latest financial results
Registered Office:
Discovery Drive, Cambridge
Biomedical Campus,
Cambridge, CB2 0AX, UK
+44 (0) 1223 696 000
VIEW PRODUCTS
© Abcam plc. all rights reserved.
Abcam plc is incorporated in England and Wales, its main country of operation in the UK. Use of this website is subject to our Terms and Conditions of use and our Privacy Policy. Share price and news information on this site is updated dynamically from external data feeds.
Website by FisherPaul